Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group ; volume:13 ; number:1 ; day:11 ; month:10 ; year:2013 ; pages:1-6 ; date:12.2013
BMC cancer ; 13, Heft 1 (11.10.2013), 1-6, 12.2013

Contributor: Emile, Jean-François
Tisserand, Julie
Bergougnoux, Loic
Nowak, Frédérique
Faucher, Gladwys
Surel, Sylvie
Lamy, Aude
Lecorre, Delphine
Helias-Rodzewicz, Zofia
Hofman, Paul
Sabourin, Jean-Christophe
Laurent-Puig, Pierre
SpringerLink (Online service)

DOI: 10.1186/1471-2407-13-472

URN: urn:nbn:de:1111-201603047597

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Emile, Jean-François
Tisserand, Julie
Bergougnoux, Loic
Nowak, Frédérique
Faucher, Gladwys
Surel, Sylvie
Lamy, Aude
Lecorre, Delphine
Helias-Rodzewicz, Zofia
Hofman, Paul
Sabourin, Jean-Christophe
Laurent-Puig, Pierre
SpringerLink (Online service)

Other Objects (12)

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Abschnitt

Braf, Albin

Bild

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Abschnitt

Braf, Albin

Bild

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Abschnitt

Braf, Albin

Bild

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Braf, Albin

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Braf, Albin

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Variations of BRAF mutant allele percentage in melanomas

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Braf, Albin

Brautpaar Braf

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy

Related objects

Reset password